Olympic Games Champion Nikki Stone and Chronic Pain Experts, Inspire Through                                 Webcast Series

WHAT:

The American Society of Pain Educators (ASPE) launches today at 9 AM EST, the second of a three-part Webcast series: 'Is Your Persistent Chronic Pain Weighing You Down?' at www.painawareness.org. This Webcast addresses the importance of proper weight control in managing chronic pain.

WHO:

— Inspirational testimony from Olympic Gold Medalist and chronic pain sufferer Nikki Stone.

— Practical pain management tips from Dr. Warren A. Katz, Clinical Professor of Medicine at the University of Pennsylvania School of Medicine and Associate of the Rothman Institute.

WHY:

While maintaining a healthy weight is important for a number of health-related reasons, it is particularly important for the more than 50 million Americans who suffer with persistent chronic pain. The significance for chronic pain sufferers to maintain a healthy diet and weight was underscored in the recent PRICARA(R) Chronic Pain Barometer online survey of 500 American chronic pain sufferers 18 years or older:

— 86 percent of respondents stated that healthy changes to their diet helped to manage their chronic pain.

— Nearly half of chronic pain sufferers (approximately 46 percent) agreed controlling their weight helped them to manage their chronic pain.

The Webcast series was developed to addresses everyday concerns for those who suffer with persistent chronic pain on the topics of exercise, weight control, and relationships, including intimacy. The first Webcast on exercise is currently archived at www.painawareness.org.

Note: Funding for ASPE and Webcast series was provided by PRICARA(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. All experts featured in the Webcasts and Nikki Stone are paid consultants for PRICARA(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

More Information

For more information, please contact: Redza Ibrahim, The American Society of Pain Educators at (973) 679-4485, or Sarah Bailey, Ruder Finn Public Relations at (212) 715-1619.

About Nikki Stone, Olympic Gold Medalist

Best known for being the first American to win a gold medal in inverted aerial skiing, Nikki Stone understands what it is like to be living with persistent chronic pain, after experiencing a back injury from a skiing accident. Months after the injury, Nikki's pain continued on a daily basis and made it difficult for her to perform once simple activities. Her doctor diagnosed her as having persistent chronic pain and worked with her to develop a pain management plan. The plan that worked for Nikki included a prescription medication, which helped manage her pain so that she could participate in physical therapy to strengthen the muscles in her back. With the combination of medication, physical therapy, doctor supervision and tireless motivation, Nikki was able to work her way back to competing and became the first American to win a gold medal in inverted aerial skiing. Today, Nikki hopes to motivate others suffering with chronic pain to speak with their doctors to find a program to manage their pain.

About the Webcast Series

Over the coming months, each Webcast will be featured on www.painawareness.org, commencing in July. This Webcast is meant for educational purposes only, and every effort has been made to ensure that the information presented is accurate. Information presented in the Webcasts is not intended to replace the care prescribed by a healthcare professional.

The opinions expressed in the Webcasts are those of the speakers, presenters and Ortho-McNeil-Janssen Pharmaceuticals, Inc., and may not necessarily reflect the positions of the ASPE, or the Webhost. The appearance of the ASPE name and logo in the Webcasts does not constitute an endorsement of any products, services or information mentioned. The ASPE does not imply discrimination against other similar products or services.

Funding for ASPE and Webcast series was provided by PRICARA(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

All experts featured in the Webcasts and Nikki Stone are paid consultants for PRICARA(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

The PRICARA(R) Chronic Pain Barometer survey was conducted online from March 28-31, 2008, in partnership with HCD Research, Inc. on behalf of PRICARA(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., the marketer of ULTRAM(R) ER (tramadol HCl) extended release tablets, and involved 500 American adults, ages 18 and older, who self-identified as suffering from chronic pain.

About the American Society of Pain Educators (ASPE)

The ASPE is a 501(c)(3) non-profit professional organization dedicated to improving the standards of clinical pain practice. The goal of the ASPE is to promote optimal quality of life and physical functioning for pain sufferers by providing high-quality pain education training and continuing education programming for healthcare professionals.

The ASPE also provides educational opportunities for clinicians who wish to become Certified Pain Educators (CPEs). CPEs serve as specialized resources for pain management in their clinical settings, educating their professional colleagues-as well as patients, families and caregivers-on ways to relieve pain by the safest means possible. As the Joint Commission on Accreditation of Healthcare Organizations requires pain management education in all of its accredited institutions, the ASPE's goal is to eventually have a CPE in every JCAHO-accredited facility.

About ULTRAM(R) ER (tramadol HCl) Extended Release Tablets

ULTRAM(R) ER is used to manage moderate to moderately severe chronic pain in adults who need to be treated around the clock for their pain for an extended period of time. For more information, please visit www.ultram-er.com.

IMPORTANT SAFETY INFORMATION

Do not take ULTRAM(R) ER if you have had an allergic reaction to tramadol, codeine, or other opioids in the past.

ULTRAM(R) ER tablets must be swallowed whole. Do not chew, crush or split the tablet before swallowing. This can lead to overdose and possible serious injury including death. Use of alcohol should be avoided when taking ULTRAM(R) ER.

The maximum daily dose of ULTRAM(R) ER is 300 mg. Do not change your dose or stop taking ULTRAM(R) ER without talking with your doctor first.

Talk with your doctor about all the medications you are taking. These may include antidepressants, tranquilizers, hypnotics or other opioid pain medicines. ULTRAM(R) ER may impair your ability to perform potentially hazardous tasks, such as driving a car or operating machinery.

Seizures have been reported in people taking tramadol, the medicine in ULTRAM(R) ER. The risk of seizures is increased with doses of tramadol above the recommended range. Use of tramadol increases the risk of seizures in people taking antidepressants, other opioids, or other drugs that can cause seizures. Risk of convulsions may also increase in people with epilepsy or a history of seizures. ULTRAM(R) ER may be associated with a potentially life-threatening condition when taken together with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) (classes of drugs for depression or other disorders), triptans, lithium, or St. John's Wort. Some common SSRIs are Paxil(R) (paroxetine), Prozac(R)/Sarafem(R) (fluoxetine), and Zoloft(R) (sertraline). Some common SNRIs are Cymbalta(R) (duloxetine) and Effexor(R) (venlafaxine). Some common triptans are Axert(R) (almotriptan), Imitrex(R) (sumatriptan), and Relpax(R) (eletriptan).

If you experience symptoms such as restlessness, hallucinations, loss of coordination, fast heartbeat, rapid changes in blood pressure, increased body temperature, overactive reflexes, nausea, vomiting, and diarrhea, contact your doctor immediately.

ULTRAM(R) ER, like other opioids, can be abused or cause dependence. People who are suicidal or have a history of drug addiction should not take ULTRAM(R) ER. Do not take more than the recommended dose of ULTRAM(R) ER. Taking more than the recommended dose of ULTRAM(R) ER, alone or in combination with alcohol or medications such as tranquilizers, hypnotics or other opioids, can cause respiratory depression, seizures, overdose and possibly death.

Tell your doctor about all your medical conditions and if you are pregnant, think you might be pregnant or are trying to become pregnant.

The most common side effects reported with ULTRAM(R) ER were dizziness, nausea, constipation, headache, and drowsiness.

Please see full Prescribing Information available at www.ultram-er.com

Paxil and Imitrex are registered trademarks of GlaxoSmithKline. Prozac and Cymbalta are registered trademarks of Eli Lilly. Sarafem is a registered trademark of Warner Chilcott. Zoloft and Relpax are registered trademarks of Pfizer, Inc. Effexor is a registered trademark of Wyeth. Axert is a registered trademark of Almirall Prodesfarma.

Note to Editor: September is National Pain Awareness Month

SOURCE The American Society of Pain Educator

Comments

comments